Botulinum toxin treatment in neurological practice: How much does it really cost? A prospective cost-effectiveness study

Journal of Neurology

Volumn 258, Issue 9, 2011, Pages 1670-1675

  Burbaud, Pierre ^a   Ducerf, Camille ^a   Cugy, Emmanuelle ^b   Dubos, Jean Louis ^a   Muller, François ^b   Guehl, Dominique ^a   Dehail, Patrick ^b   Cugy, Didier ^a   Moore, Nicholas ^b   Lagueny, Alain ^b   Joseph, Pierre Alain ^b  

^a HÔPITAL PELLEGRIN   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Botulinum toxin; Cost effectiveness study; Dystonia; Spasticity

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BLEPHAROSPASM; CERVICAL DYSTONIA; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DYSTONIA; FACE HEMISPASM; FOLLOW UP; GENERALIZED DYSTONIA; HUMAN; MAJOR CLINICAL STUDY; MEIGE SYNDROME; MUSCLE RIGIDITY; MUSCLE SPASM; OCCUPATIONAL DYSTONIA; OROMANDIBULAR DYSTONIA; PRIORITY JOURNAL; SPASTICITY; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; NEUROMUSCULAR DISEASES; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES;

EID: 80054764765     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-5998-9     Document Type: Article

References (23)

1. R Balkrishnan FT Camacho BP Smith JS Shilt LK Jacks LA Koman KL Rascati JF Mooney 3rd 2002 Cost impact of botulinum toxin use in Medicaid-enrolled children with cerebral palsy J South Orthop Assoc 11 71 79 12741586
2. Bodenez C, Bernat I, Willer JC, Barre P, Lamas G, Tankere F (2010) Facial nerve decompression for idiopathic Bell's palsy: report of 13 cases and literature review. J Laryngol Otol 124:272-278
3. C Brefel-Courbon M Simonetta-Moreau C More O Rascol M Clanet JL Montastruc M Lapeyre-Mestre 2000 A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis Clin Neuropharmacol 23 203 207 11020124 10.1097/00002826-200007000-00006 1:CAS:528:DC%2BD3cXnsFegtLo%3D
4. M Cioni A Esquenazi B Hirai 2006 Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot Am J Phys Med Rehabil 85 600 606 16788391 10.1097/01.phm.0000223216.50068. bc (Pubitemid 43941567)
5. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005) Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev:CD004900
6. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev:CD003633
7. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005) Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev:CD004899
8. RC Dodel A Kirchner R Koehne-Volland G Kunig A Ceballos-Baumann M Naumann A Brashear HP Richter TD Szucs WH Oertel 1997 Costs of treating dystonias and hemifacial spasm with botulinum toxin A Pharmacoeconomics 12 695 706 10175981 10.2165/00019053-199712060-00009 1:STN:280:DyaK1c7isFahtw%3D%3D (Pubitemid 27520882)
9. CM Gudex MR Hawthorne AG Butler PO Duffey 1997 Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysis Pharmacoeconomics 12 675 684 10175979 10.2165/00019053-199712060-00007 1:STN:280:DyaK1c7isFahsQ%3D%3D (Pubitemid 27520880)
10. SW Hung C Hamani AM Lozano YY Poon P Piboolnurak JM Miyasaki AE Lang JO Dostrovsky WD Hutchison E Moro 2007 Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia Neurology 68 457 459 17283323 10.1212/01.wnl.0000252932.71306.89 1:STN:280:DC%2BD2s%2Fot1ygsA%3D%3D (Pubitemid 46208751)
11. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M (2010) Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 26:1983-1992
12. ZH Kiss K Doig-Beyaert M Eliasziw J Tsui A Haffenden O Suchowersky 2007 The Canadian multicentre study of deep brain stimulation for cervical dystonia Brain 130 2879 2886 17905796 10.1093/brain/awm229 (Pubitemid 350033969)
13. CG Lasalvia S Pereira Lde MC da Cunha SP Kitadai 2006 Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm Arq Bras Oftalmol 69 701 705 17187139 10.1590/S0004- 27492006000500016 (Pubitemid 44816786)
14. MP Mitchell K Schaecher HE Cannon M Speckman 2008 Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization J Manag Care Pharm 14 442 450 18597573
15. E Moro P Piboolnurak T Arenovich SW Hung YY Poon AM Lozano 2009 Pallidal stimulation in cervical dystonia: clinical implications of acute changes in stimulation parameters Eur J Neurol 16 506 512 19207733 10.1111/j.1468-1331. 2008.02520.x 1:STN:280:DC%2BD1M3mtVGluw%3D%3D
16. H Rodgers L Shaw C Price F van Wijck M Barnes L Graham G Ford P Shackley N Steen 2008 Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A Trials 9 59 18947418 10.1186/1745-6215-9-59
17. FJ Ruiz JF Guest A Lehmann AM Davie K Guttler O Schluter G Dreiss 2004 Costs and consequences of botulinum toxin type A use. Management of children with cerebral palsy in Germany Eur J Health Econ 5 227 235 15714343 10.1007/s10198-004-0224-7 (Pubitemid 39382521)
18. NY Siddiqui CL Amundsen AG Visco ER Myers JM Wu 2009 Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence J Urol 182 2799 2804 19837427 10.1016/j.juro.2009. 08.031
19. DM Simpson A Blitzer A Brashear C Comella R Dubinsky M Hallett J Jankovic B Karp CL Ludlow JM Miyasaki M Naumann Y So 2008 Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 70 1699 1706 18458230 10.1212/01.wnl.0000311389.26145.95 1:CAS:528:DC%2BD1cXnsFGgtrs%3D (Pubitemid 351644138)
20. M Sindou Y Keravel 2009 Neurosurgical treatment of primary hemifacial spasm with microvascular decompression Neurochirurgie 55 236 247 19329131 10.1016/j.neuchi.2009.02.012 1:STN:280:DC%2BD1M3osVyntQ%3D%3D
21. A Ward G Roberts J Warner S Gillard 2005 Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity J Rehabil Med 37 252 257 16024483 10.1080/16501970510027312 (Pubitemid 41025335)
22. AP Yelnik 2004 Pharmacology and upper limb poststroke spasticity: a review. International Society of Prosthetics and Orthotics Ann Readapt Med Phys 47 575 589 15465163 1:STN:280:DC%2BD2cvpsVylsg%3D%3D (Pubitemid 39311009)
23. AP Yelnik O Simon D Bensmail E Chaleat-Valayer P Decq P Dehail V Quentin P Marque B Parratte F Pellas M Rousseaux JM Trocello M Uzzan N Dumarcet 2009 Drug treatments for spasticity Ann Phys Rehabil Med 52 746 756 19892619 1:STN:280:DC%2BD1MfhtFChtg%3D%3D